桂林三金: 关于为孙公司提供担保的进展公告

Summary of Key Points Core Viewpoint - Guilin Sanjin Pharmaceutical Co., Ltd. has provided a guarantee for its wholly-owned subsidiary, Baoshan Biological Pharmaceutical Technology (Shanghai) Co., Ltd., amounting to RMB 20 million, which is part of a total guarantee limit of up to RMB 270 million approved by the board and shareholders [1][2][3]. Group 1: Guarantee Overview - The actual guarantee balance for the company and its subsidiaries is RMB 300.6 million, accounting for 9.99% of the latest audited net assets [1][3]. - Baoshan Biological has an asset-liability ratio exceeding 70% [1][2]. - The guarantee is structured as a joint liability guarantee for a credit limit application to Xiamen International Bank Shanghai Branch [1][3]. Group 2: Approval Process - The guarantee limit was approved during the 13th meeting of the 8th Board of Directors on April 24, 2025, and at the 2024 Annual General Meeting on May 16, 2025 [2]. - The total guarantee amount for Baoshan Biological and another subsidiary, Baifan Biological, is capped at RMB 270 million, with the guarantee methods including joint liability and collateral [2]. Group 3: Guarantee Agreement Details - The guarantor is Guilin Sanjin Pharmaceutical Co., Ltd., the creditor is Xiamen International Bank Shanghai Branch, and the debtor is Baoshan Biological [3]. - The guarantee covers all principal debts, interest, penalties, and related costs, with a guarantee period extending three years from the debt fulfillment deadline [3].